BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 29907535)

  • 1. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
    Lin SY; Chiu YW; Lu PL; Hwang SJ; Chen TC; Hsieh MH; Chen YH
    J Microbiol Immunol Infect; 2019 Feb; 52(1):158-162. PubMed ID: 29907535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 3. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
    Sterling TR; Moro RN; Borisov AS; Phillips E; Shepherd G; Adkinson NF; Weis S; Ho C; Villarino ME;
    Clin Infect Dis; 2015 Aug; 61(4):527-35. PubMed ID: 25904367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved treatment completion with shorter treatment regimens for latent tuberculous infection.
    Macaraig MM; Jalees M; Lam C; Burzynski J
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1344-1349. PubMed ID: 30355415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis.
    Chen YM; Liao TL; Chen HH; Chen DY
    Ann Rheum Dis; 2018 Nov; 77(11):1688-1689. PubMed ID: 29674320
    [No Abstract]   [Full Text] [Related]  

  • 11. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
    Belknap R; Holland D; Feng PJ; Millet JP; Caylà JA; Martinson NA; Wright A; Chen MP; Moro RN; Scott NA; Arevalo B; Miró JM; Villarino ME; Weiner M; Borisov AS;
    Ann Intern Med; 2017 Nov; 167(10):689-697. PubMed ID: 29114781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
    Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
    Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
    Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
    Sterling TR; Scott NA; Miro JM; Calvet G; La Rosa A; Infante R; Chen MP; Benator DA; Gordin F; Benson CA; Chaisson RE; Villarino ME;
    AIDS; 2016 Jun; 30(10):1607-15. PubMed ID: 27243774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
    Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
    BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
    Yu YY; Tsao SM; Yang WT; Huang WC; Lin CH; Chen WW; Yang SF; Chiou HL; Huang YW
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31892222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study.
    Yang H; Yang Y; Hu ZD; Xia L; Liu XH; Yu X; Ma JY; Li T; Lu SH
    PLoS One; 2021; 16(6):e0253159. PubMed ID: 34115804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
    Swindells S; Ramchandani R; Gupta A; Benson CA; Leon-Cruz J; Mwelase N; Jean Juste MA; Lama JR; Valencia J; Omoz-Oarhe A; Supparatpinyo K; Masheto G; Mohapi L; da Silva Escada RO; Mawlana S; Banda P; Severe P; Hakim J; Kanyama C; Langat D; Moran L; Andersen J; Fletcher CV; Nuermberger E; Chaisson RE;
    N Engl J Med; 2019 Mar; 380(11):1001-1011. PubMed ID: 30865794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.